These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20658801)

  • 1. Low-dose doxepin: in the treatment of insomnia.
    Weber J; Siddiqui MA; Wagstaff AJ; McCormack PL
    CNS Drugs; 2010 Aug; 24(8):713-20. PubMed ID: 20658801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia.
    Krystal AD; Durrence HH; Scharf M; Jochelson P; Rogowski R; Ludington E; Roth T
    Sleep; 2010 Nov; 33(11):1553-61. PubMed ID: 21102997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.
    Scharf M; Rogowski R; Hull S; Cohn M; Mayleben D; Feldman N; Ereshefsky L; Lankford A; Roth T
    J Clin Psychiatry; 2008 Oct; 69(10):1557-64. PubMed ID: 19192438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.
    Hajak G; Rodenbeck A; Voderholzer U; Riemann D; Cohrs S; Hohagen F; Berger M; Rüther E
    J Clin Psychiatry; 2001 Jun; 62(6):453-63. PubMed ID: 11465523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose doxepin for the treatment of insomnia: emerging data.
    Goforth HW
    Expert Opin Pharmacother; 2009 Jul; 10(10):1649-55. PubMed ID: 19496739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia.
    Hajak G; Rodenbeck A; Adler L; Huether G; Bandelow B; Herrendorf G; Staedt J; Rüther E
    Pharmacopsychiatry; 1996 Sep; 29(5):187-92. PubMed ID: 8895944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia.
    Roth T; Rogowski R; Hull S; Schwartz H; Koshorek G; Corser B; Seiden D; Lankford A
    Sleep; 2007 Nov; 30(11):1555-61. PubMed ID: 18041488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.
    Lankford A; Rogowski R; Essink B; Ludington E; Heith Durrence H; Roth T
    Sleep Med; 2012 Feb; 13(2):133-8. PubMed ID: 22197474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective histamine H(1) antagonism: a novel approach to insomnia using low-dose doxepin.
    Owen RT
    Drugs Today (Barc); 2009 Apr; 45(4):261-7. PubMed ID: 19499091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose doxepin (Silenor) for insomnia.
    Med Lett Drugs Ther; 2010 Oct; 52(1348):79-80. PubMed ID: 20885342
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.
    Krystal AD; Lankford A; Durrence HH; Ludington E; Jochelson P; Rogowski R; Roth T
    Sleep; 2011 Oct; 34(10):1433-42. PubMed ID: 21966075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histamine-1 receptor antagonism for treatment of insomnia.
    Vande Griend JP; Anderson SL
    J Am Pharm Assoc (2003); 2012; 52(6):e210-9. PubMed ID: 23229983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.
    Rodenbeck A; Cohrs S; Jordan W; Huether G; Rüther E; Hajak G
    Psychopharmacology (Berl); 2003 Dec; 170(4):423-8. PubMed ID: 13680082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials.
    Yeung WF; Chung KF; Yung KP; Ng TH
    Sleep Med Rev; 2015 Feb; 19():75-83. PubMed ID: 25047681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.
    Riemann D; Voderholzer U; Cohrs S; Rodenbeck A; Hajak G; Rüther E; Wiegand MH; Laakmann G; Baghai T; Fischer W; Hoffmann M; Hohagen F; Mayer G; Berger M
    Pharmacopsychiatry; 2002 Sep; 35(5):165-74. PubMed ID: 12237787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -- a randomized study.
    Rios Romenets S; Creti L; Fichten C; Bailes S; Libman E; Pelletier A; Postuma RB
    Parkinsonism Relat Disord; 2013 Jul; 19(7):670-5. PubMed ID: 23561946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic usage of low-dose doxepin hydrochloride.
    Singh H; Becker PM
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1295-305. PubMed ID: 17685877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people.
    Rojas-Fernandez CH; Chen Y
    Can Pharm J (Ott); 2014 Sep; 147(5):281-9. PubMed ID: 25364337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of insomnia with tricyclic antidepressants: a meta-analysis of polysomnographic randomized controlled trials.
    Liu Y; Xu X; Dong M; Jia S; Wei Y
    Sleep Med; 2017 Jun; 34():126-133. PubMed ID: 28522080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin in insomniac patients and effects of sleep medication.
    Rodenbeck A; Hajak G; Huether G
    Adv Exp Med Biol; 1996; 398():113-7. PubMed ID: 8906252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.